Details

Autor(en) / Beteiligte

• WEIDE, Benjamin
• ZELBA, Henning
• SCHADENDORF, Dirk
• BIITTNER, Petra
• GARBE, Claus
• PAWELEC, Graham
• DERHOVANESSIAN, Evelyna
• PFLUGFELDER, Annette
• EIGENTLER, Thomas K
• DI GIACOMO, Anna Maria
• MAIO, Michele
• AARNTZEN, Erik H. J. G
• DE VRIES, I. Jolanda M
• SUCKER, Antje

Titel

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

Ist Teil von

• Journal of clinical oncology, 2012-05, Vol.30 (15), p.1835-1841

Ort / Verlag

Alexandria, VA: American Society of Clinical Oncology

Erscheinungsjahr

2012

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis. We examined 84 patients with follow-up after analysis (cohort A), 18 long-term survivors with an extraordinarily favorable course of disease before analysis (> 24 months survival after first occurrence of distant metastases; cohort B), and 14 healthy controls. Circulating antigen-reactive T cells were characterized by intracellular cytokine staining after in vitro stimulation. In cohort A patients, the presence of T cells responding to peptides from NY-ESO-1, Melan-A, or MAGE-3 and the M category according to the American Joint Committee on Cancer classification were significantly associated with survival. T cells responding to NY-ESO-1 and Melan-A (hazard ratios, 0.29 and 0.18, respectively) remained independent prognostic factors in Cox regression analysis and were superior to the M category in predicting outcome. Median survival of patients possessing T cells responding to NY-ESO-1, Melan-A, or both was 21 months, compared with 6 months for all others. NY-ESO-1-responsive T cells were detected in 70% of cohort A patients surviving > 18 months and in 50% of cohort B patients. Melan-A responses were found in 42% and 47% of patients in cohorts A and B, respectively. In contrast, the proportion was only 22% for NY-ESO-1 and 23% for Melan-A in those who died within 6 months. The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. Our findings support the therapeutic relevance of Melan-A and NY-ESO-1 as targets for immunotherapy.